

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF Art Unit: 1618
Pruschy, Martin Examiner: Gembelh, Shirley V
INTERNATIONAL APPLICATION NO: PCT/EP2004/002610
FILED: March 12, 2004
U.S. APPLICATION NO: 10/549978
35 USC §371 DATE: November 15, 2006
FOR: Treatment of Proliferative Diseases with Epothilone Derivatives and
Radiation

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-7824

Date: June 29, 2011

Respectfully submitted,


George Dohmann
Attorney for Applicant
Reg. No. 33,593